335 related articles for article (PubMed ID: 33203424)
21. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiñol L; Faber EA; Voorhees P; Mateos MV; Marquez L; Feng H; Desai A; van de Velde H; Elliott J; Shi H; Dow E; Jobanputra N; Esseltine DL; Niculescu L; Anderson KC; Lonial S; Richardson PG
Br J Haematol; 2017 Aug; 178(4):547-560. PubMed ID: 28466536
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
Sandy EB; Weerasinghe C; Terjanian T
J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813
[TBL] [Abstract][Full Text] [Related]
23. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
24. [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Nakamura S; Yata K; Jinno T; Harada T; Fujii S; Miki H; Nakano A; Kagawa K; Takeuchi K; Ozaki S; Abe M; Matsumoto T
Rinsho Ketsueki; 2010 Aug; 51(8):690-5. PubMed ID: 20805677
[TBL] [Abstract][Full Text] [Related]
25. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database.
Xia S; Gong H; Zhao Y; Guo L; Wang Y; Ma R; Zhang B; Sarangdhar M; Noguchi Y; Yan M
Clin Pharmacol Ther; 2023 Jul; 114(1):211-219. PubMed ID: 37086211
[TBL] [Abstract][Full Text] [Related]
26. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
27. Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy.
Zhang Q; Zu C; Meng Y; Lyu Y; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):144-150. PubMed ID: 36161293
[TBL] [Abstract][Full Text] [Related]
28. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
29. Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.
Ibarra G; Peña M; Abril L; Senín A; Maluquer C; Clapés V; Baca C; Bustamante G; Sureda A; Oriol A
Eur J Haematol; 2021 Aug; 107(2):246-254. PubMed ID: 33934417
[TBL] [Abstract][Full Text] [Related]
30. Demyelinating polyradiculoneuritis in patients with multiple myeloma: the other side of bortezomib-induced neurotoxicity.
Gendreau S; Berzero G; Tafani C; Raynouard I; Ricard D; Malfuson JV; Viala K; Debs R; Houillier C; Diamanti L; Marchioni E; Lenglet T; Ouzegdouh M; Bihan K; Gilardin L; Psimaras D
Acta Oncol; 2020 Apr; 59(4):484-489. PubMed ID: 32122210
[No Abstract] [Full Text] [Related]
31. Bortezomib-containing regimens are effective in multiple myeloma--results of a non-interventional phase IV study.
Knauf W; Tapprich C; Schlag R; Schütz S; Alkemper B; Gaede B; Reschke D; Schmits R; Schwarzer A
Oncol Res Treat; 2015; 38(4):167-73. PubMed ID: 25877940
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
33. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
Keating M; Dasanu CA
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27899388
[TBL] [Abstract][Full Text] [Related]
34. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
[TBL] [Abstract][Full Text] [Related]
35. Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study.
Terpos E; Gobbi M; Potamianou A; Lahaye M; Couturier C; Cavo M
Eur J Haematol; 2018 Jan; 100(1):10-19. PubMed ID: 28801967
[TBL] [Abstract][Full Text] [Related]
36. Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients.
Zhang L; Mager DE
J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):77-90. PubMed ID: 31939004
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of bortezomib-based therapy in myeloma.
Djebbari F; Srinivasan A; Vallance G; Moore S; Kothari J; Ramasamy K
PLoS One; 2018; 13(12):e0208920. PubMed ID: 30540831
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
[TBL] [Abstract][Full Text] [Related]
40. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
